News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,422 Results
Type
Article (42327)
Company Profile (294)
Press Release (672801)
Section
Business (210373)
Career Advice (2091)
Deals (36629)
Drug Delivery (106)
Drug Development (83013)
Employer Resources (175)
FDA (16546)
Job Trends (15395)
News (355904)
Policy (33880)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (2)
Adcomms (21)
Allergies (84)
Alliances (51366)
ALS (85)
Alzheimer's disease (1364)
Antibody-drug conjugate (ADC) (115)
Approvals (16546)
Artificial intelligence (241)
Autoimmune disease (15)
Automation (14)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (188)
Bladder cancer (56)
Brain cancer (26)
Breast cancer (248)
Cancer (1992)
Cardiovascular disease (156)
Career advice (1749)
Career pathing (30)
CAR-T (141)
Cell therapy (397)
Cervical cancer (17)
Clinical research (67194)
Collaboration (777)
Compensation (451)
Complete response letters (24)
COVID-19 (2652)
CRISPR (40)
C-suite (209)
Cystic fibrosis (101)
Data (1907)
Decentralized trials (2)
Denatured (26)
Depression (39)
Diabetes (245)
Diagnostics (6411)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (112)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (85)
Earnings (87814)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114445)
Executive appointments (641)
FDA (17652)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (692)
Gene editing (101)
Generative AI (20)
Gene therapy (286)
GLP-1 (716)
Government (4499)
Grass and pollen (4)
Guidances (48)
Healthcare (18986)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (111)
Indications (27)
Infectious disease (2781)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (85)
Interviews (322)
IPO (16762)
IRA (47)
Job creations (4055)
Job search strategy (1492)
Kidney cancer (9)
Labor market (34)
Layoffs (471)
Leadership (16)
Legal (8367)
Liver cancer (71)
Lung cancer (289)
Lymphoma (131)
Machine learning (2)
Management (59)
Manufacturing (276)
MASH (61)
Medical device (13398)
Medtech (13403)
Mergers & acquisitions (20325)
Metabolic disorders (641)
Multiple sclerosis (67)
NASH (17)
Neurodegenerative disease (80)
Neuropsychiatric disorders (26)
Neuroscience (1842)
NextGen: Class of 2025 (6636)
Non-profit (4524)
Northern California (2395)
Now hiring (37)
Obesity (350)
Opinion (226)
Ovarian cancer (72)
Pain (85)
Pancreatic cancer (77)
Parkinson's disease (131)
Partnered (18)
Patents (205)
Patient recruitment (94)
Peanut (49)
People (59023)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20836)
Phase II (29565)
Phase III (22161)
Pipeline (969)
Podcasts (74)
Policy (119)
Postmarket research (2654)
Preclinical (8833)
Press Release (68)
Prostate cancer (92)
Psychedelics (31)
Radiopharmaceuticals (248)
Rare diseases (367)
Real estate (6251)
Recruiting (67)
Regulatory (22968)
Reports (46)
Research institute (2365)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (123)
Series B (78)
Service/supplier (12)
Sickle cell disease (52)
Southern California (2070)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3721)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (45)
United States (21060)
Vaccines (672)
Venture capitalists (37)
Webinars (12)
Weight loss (241)
Women's health (33)
Worklife (15)
Date
Today (27)
Last 7 days (568)
Last 30 days (2636)
Last 365 days (34009)
2025 (7758)
2024 (35770)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33141)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (780)
Alabama (49)
Alaska (7)
Arizona (230)
Arkansas (14)
Asia (40567)
Australia (6497)
California (5472)
Canada (1864)
China (477)
Colorado (247)
Connecticut (257)
Delaware (126)
Europe (86478)
Florida (812)
Georgia (190)
Idaho (57)
Illinois (501)
India (24)
Indiana (297)
Iowa (9)
Japan (142)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (831)
Massachusetts (4148)
Michigan (210)
Minnesota (368)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1562)
New Mexico (29)
New York (1568)
North Carolina (928)
North Dakota (7)
Northern California (2395)
Ohio (190)
Oklahoma (14)
Oregon (38)
Pennsylvania (1244)
Puerto Rico (9)
Rhode Island (26)
South America (1160)
South Carolina (18)
South Dakota (1)
Southern California (2070)
Tennessee (92)
Texas (819)
Utah (165)
Virginia (135)
Washington D.C. (57)
Washington State (513)
West Virginia (3)
Wisconsin (50)
715,422 Results for "paratek pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
March 20, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
March 20, 2025
·
17 min read
Genetown
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
Paratek Pharmaceuticals, Inc. today announced that three new pre-clinical studies with NUZYRA ® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).
April 18, 2024
·
4 min read
Business
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer
Paratek Pharmaceuticals, Inc. announced two key executive team promotions.
January 16, 2024
·
3 min read
Genetown
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
Paratek Pharmaceuticals, Inc. today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia.
December 13, 2023
·
2 min read
Press Releases
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
November 15, 2024
·
6 min read
Genetown
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Paratek Pharmaceuticals, Inc. today announces that new data from NUZYRA ® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.
October 5, 2023
·
3 min read
Genetown
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Gurnet Point Capital and Novo Holdings A/S announced the completion of their acquisition of Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.
September 21, 2023
·
4 min read
Press Releases
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
October 14, 2024
·
8 min read
Genetown
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announced positive top-line efficacy data for NUZYRA® as post-exposure prophylaxis in a non-human primate model of inhalational anthrax.
March 5, 2024
·
4 min read
1 of 71,543
Next